Serotonergic drugs in the treatment of depressive and anxiety disorders

Human Psychopharmacology

Volumn 15, Issue 5, 2000, Pages 315-336

  Den Boer, Johan A ^a   Bosker, Fokko J ^a   Slaap, Bernhard R ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anxiety; Depression; Generalized anxiety disorder; Obsessive compulsive disorder; Panic disorder; Serotonin; Social phobia

Indexed keywords

SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ANXIETY NEUROSIS; DEPRESSION; HUMAN; OBSESSION; PANIC; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SOCIAL PHOBIA;

EID: 0033940313     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-1077(200007)15:5<315::AID-HUP204>3.0.CO;2-Y     Document Type: Review

References (193)

1. Aguglia E, Casacchia M, Cassano GB, Favarelli C, Ferrari G, Giordano P, Pancheri P, Ravizza L, Trabucchi M, Bolino F. 1993. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 8: 197-202.
2. Amsterdam J. 1992. Gepirone, a selective serotonin (5HT1A) partial agonist, in the treatment of major depression. Prog Neuropsychopharmacol Biol Psychiatry 16: 271-280.
3. Anderson IM. 1998. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7(Suppl. 1): 11-17.
4. Anderson IM, Tomenson BM. 1995. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 310: 1433-1438.
5. Ansseau M, Darimont P, Lecoq A, De Nayer A, Evrard JL, Kremer P, Devoitille JM, Dierick M, Mertens C, Mesotten F. 1994. Controlled comparison of nefazodone and amitriptyline in major depressive inpatients. Psychopharmacology 115: 254-260.
6. Anton SF, Robinson DS, Roberts DL, Kensler TT, English PA, Archibald DG. 1994. Long-term treatment of depression with nefazodone. Psychopharmacol Bull 30: 165-169.
7. Artigas F. 1993. 5-HT and antidepressants; new views from microdialysis studies. Trends Pharmacol Sci 14: 262-263.
8. Artigas F, Perez V, Alvarez E. 1994. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51: 248-251.
9. Baber N, Palmer JL, Frazer NM, Pritchard JF. 1992. Clinical pharmacology of ondansetron I postoperative nausea and vomiting. Eur J Anaesthesiol 9(Suppl. 6): 11-18.
10. Bach M, Aigner M, Lenz G. 1997. Ritanserin as adjunct to fluoxetine treatment of OCD patients with psychotic features [Letter]. Pharmacopsychiatry 30: 28-29.
11. Bakish D, Ravindran A, Hooper C, Lapierre Y. 1994. Psychopharmacological response of patients with a DSM-III diagnosis of dysthymic disorder. Psychopharmacol Bull 30: 53-59.
12. Baldwin D, Bobes J, Stein DJ, Scharwächter I, Faure M. 1999. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 175: 120-126.
13. Baldwin DS, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, Pover GH, Ascher A. 1996. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate to severe depression. J Clin Psychiatry 57(Suppl. 2): 46-52.
14. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IV. 1998. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155: 36-42.
15. Bech P. 1989. Clinical effects of selective serotonin reuptake inhibitors. In Clinical Pharmacology in Psychiatry, Dahl SG, Gram LF (eds). Springer: Berlin; 81-93.
16. Bech P, Cialdella P. 1992. Citalopram in depression: meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 6(Suppl. 5): 45-54.
17. 3 antagonist ondansetron in social phobia. Presented at the 33rd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 12-16 December 1994.
18. Bennie EH, Mullin JM, Martindale JJ. 1995. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 56: 229-237.
19. Berman RM, Darnell AM, Miller HL, Arnand A, Charney DS. 1997. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 154: 37-43.
20. Bersani G, Pozzi F, Marini S, Grispini A, Pasini A, Ciani N. 1991. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind, placebo-controlled study with ritanserin. Acta Psychiatr Scand 83: 244-248.
21. Bisserbe J-C, Lane RM, Flament MF, Franco-Belgian OCD Study Group. 1997. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 12: 82-93.
22. Black B, Uhde TW, Tancer ME. 1992. Fluoxetine for the treatment of social phobia [Letter]. J Clin Psychopharmacol 12: 293-295.
23. Black DW, Wesner R, Bowers W, Gabel J. 1993. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50: 44-50.
24. Blier P, Bergeron R. 1995. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15: 217-222.
25. Blier P, Bergeron R. 1996. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol 11: 37-44.
26. Blier P, de Montigny C, Chaput Y. 1987. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 7(Suppl. 6): 24S-35S.
27. Borison RL, Albrecht JW, Diamond BI. 1990. Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacol Bull 26: 207-210.
28. Bouchard JM, Delaunay J, Delisle JP, Grasset N, Mermberg PF, Molczadzki M, Pagot R, Richou H, Ropert R. 1987. Citalopram versus maprotiline: a controlled, clinical multicetnre trial in depressed patients. Acta Psychiatr Scand 76: 583-592.
29. Bourin M, Malinge M. 1995. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Prog Neuropsychopharmacol Biol Psychiatry 19: 567-575.
30. Bouvard M, Mollard E, Guerin J, Cottraux J. 1997. Study and course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone. Psychother Psychosom 66: 27-32.
31. Bouwer C, Stein DJ. 1997. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment refractory depression. S Afr Med J 87(Suppl. 4): 534-537.
32. Bouwer C, Stein DJ. 1998. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 49: 79-82.
33. Boyer WF, Feighner JP. 1993. A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder. Int Clin Psychopharmacol 8: 173-176.
34. Bressa GM, Marini S, Gregori S. 1987. Serotonin S2 receptors blockage and generalized anxiety disorders. A double blind study on ritanserin and lorazepam. Int J Clin Pharmacol Res 7: 111-119.
35. Busto UE, Naranjo CA, Bremner KE, Peachey KE, Bolaga M. 1998. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects. J Psychiatry Neurosci 23: 35-44.
36. Bystritsky A, Rosen EM, Murphy KJ, Bohn P, Keys SA, Vapnik T. 1994. Double-blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1: 287-290.
37. Chaput Y, Demontigny C, Blier P. 1991. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments - An in vivo electrophysiologic study in the rat. Neuropsychopharmacology 5: 219-229.
38. Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, Quadrino LM, Heninger GR. 1986. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 47: 580-586.
39. Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O'Brien K, Ieni JR. 1996. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 57(Suppl. 2): 15-18.
40. Cohn JB, Wilcox CS. 1986. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study. J Clin Psychiatry 47: 409-412.
41. Coppen A. 1967. The biochemistry of affective disorders. Br J Psychiatry 113: 1237-1264.
42. Cutler NR, Sramek JJ, Keppel-Hesselink JM, Krol A, Roeschen J, Rickels K, Schweizer E. 1993a. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J Clin Psychopharmacol 13: 429-437.
43. Cutler N, Sramek JJ, Wardle TS, Hesselink JM, Roeschen JK. 1993b. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial. Psychopharmacol Bull 29: 303-308.
44. Cutler NR, Hesselink JM, Sramek JJ. 1994. A phase II multicenter dose-finding efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 18: 447-463.
45. Czepowicz VD, Johnson MR, Lydiard RB, Emmanuel NP, Ware MR, Mintzer OB, Walsh MD, Ballenger JC. 1995. Sertraline in social phobia [Letter]. J Clin Psychopharmacol 15: 372-373.
46. Danish University Antidepressant Group (DUAG). 1986. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 90: 131-138.
47. Danish University Antidepressant Group (DUAG). 1999. Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Clin Pharmacol Ther 66: 152-165.
48. Dannon PN, Hirschmann S, Kindler S, Iancu T, Dolberg OT, Grunhaus LJ. 1997. Pindolol augmentation in the treatment of resistant panic disorder: a double-blind placebo-controlled trial. ECNP, Vienna 1997; Abstract P.3.013.
49. Davidson JR, DuPont RL, Hedges D, Haskins JT. 1999. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60: 528-535.
50. De Wilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S. 1993. A double-blind, comparative, multicenter study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 87: 141-145.
51. Deakin JF, Graeff FG. 1991. 5-HT and mechanisms of defence. J Psychopharmacol 5: 305-315.
52. Delle-Chiaie R, Pancheri P, Casacchia M, Stratta P, Kotzalidis GD, Zibellini M. 1995. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol 15: 12-19.
53. DeMartinis NA, Schweizer E, Rickels K. 1996. An open label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 57: 245-248.
54. den Boer JA, Westenberg HGM. 1988. Effect of serotonin and noradrenaline uptake inhibitors in panic disorders; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3: 59-74.
55. den Boer JA, Westenberg HGM. 1990. Serotonin function in panic disorder, a double-blind placebo-controlled study with fluvoxamine and ritanserin. Psychopharmacology 102: 85-94.
56. den Boer JA, Westenberg HGM, Kamerbeek WD, Verhoeven WM, Kahn RS. 1987. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 2: 21-32.
57. Doogan DP, Caillard V. 1992. Sertraline in the prevention of depression. Br J Psychiatry 160: 217-222.
58. Enkelmann R. 1991. Aplrazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl) 105: 428-432.
59. Eskelius L, von Knorring L, Eberhard G. 1997. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 12: 323-331.
60. Feiger AD. 1996. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull 32: 659-665.
61. Feighner J, Tagum SD, Bennett ME, Roberts DL, Kensler TT, D'Amico MF, Hardy SA. 1998. A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. J Clin Psychiatry 59: 246-253.
62. Feighner JP. 1987. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 48(Suppl.): 3-6.
63. Feighner JP. 1999. Mechanism of action of antidepressant medications. J Clin Psychiatry 60(Suppl. 4): 4-11.
64. Feighner JP, Meredith CH, Dutt JE, Henrickson GA. 1982. A double-blind comparison of buspirone, and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 43: 103-107.
65. Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, Ecker JA, Faludi G. 1994. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 55: 234-241.
66. Franchini L, Gasperinin M, Perez J, Smeraldi E, Zanardi R. 1997. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry 58: 104-107.
67. Freeman AM, Westphal JR, Norris GT, Roggero BA, Webb PB, Freeman KL, Rush JA, Hearne EM, Evoniuk G. 1997. Efficacy of ondansetron in the treatment of generalized anxiety disorder. [Letter]. Depress Anxiety 5: 140-141.
68. Freeman C, Trimble M, Deakin J, Stokes TM, Ashford JJ. 1994. Fluvoxamine versus clomipramine in the treatment of OCD: a multi-center, randomized, double-blind, parallel group comparison. J Clin Psychiatry 55: 301-315.
69. Fuglum E, Rosenberg C, Damsbo N, Stage K, Lauritzen L, Bech P, Danish University Antidepressant Group. 1996. Screening and treating depressed patients. A comparison of two controlled citalopram trials across treatment settings: hospitalized patients vs. patients treated by their family doctors. Acta Psychiatr Scand 94: 18-25.
70. Gammans RE, Stringfellow JC, Hvizdos AJ, Seidelhamel RJ, Cohn JB, Wilcox CS, Fabre LF, Pecknold JC, Smith WT, Rickels K. 1992. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsychobiology 25: 193-201.
71. Geretsegger C, Bohmer F, Ludwig M. 1994. Paroxetine in the elderly patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 9: 25-29.
72. Goldberg HL, Finnerty R. 1982. Comparison of buspirone in two separate studies. J Clin Psychiatry 43: 87-91.
73. Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Napy LM, Rasmussen SA, Heninger GR, Charney DS. 1990. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluovoxamine and desipramine. Arch Gen Psychiatry 47: 577-585.
74. Goodman WK, Ward H, Kablinger A, Murphy T. 1997. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J Clin Psychiatry 58(Suppl. 5): 32-49.
75. Grady TA, Pigott TA, L'Heureux F, Hill JL, Bernstein SE, Murphy DL. 1993. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 150: 819-821.
76. Graeff FG, Guimaraes FS, De Andrade TG, Deakin JF. 1996. Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 54: 129-141.
77. Graves T. 1990. Ondansetron: a new entity in emesis control. DICP 24(Suppl. 11): S51-S54.
78. Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz MR, Lydiard B. 1995. A 1 year double blind, placebo-controlled, fixed-dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 10: 57-65.
79. Griez E, Pols H, Lousberg H. 1988. Serotonin antagonism in panic disorder: an open trial with ritanserin. Acta Psychiatr Belg 88: 372-377.
80. Haffmans PM, Timmerman L, Hoogduin CA. 1996. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. Int Clin Psychopharmacol 11: 157-164.
81. Haria M, Fitton A, McTavish D. 1994. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 4: 331-355.
82. Harvey KV, Balon R. 1995. Augmentation with buspirone: a review. Ann Clin Psychiatry 7: 143-147.
83. Hedges DW, Reimherr FW, Strong RE, Halls CH, Rust C. 1996. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull 32: 671-676.
84. Heller AH, Beneke M, Kuemmel B, Spencer D, Kurtz NM. 1990. Ipsapirone: evidence for efficacy in depression. Psychopharmacol Bull 26: 219-222.
85. Hjorth S. 1993. A rating scale for depression. J Neurol Neurosurg Psychiatr 23: 56-62.
86. Hoehn-Saric R, Fawcett J, Munjack DJ, Roy-Byrne PP. 1993. A multi-centre, double-blind, placebo-controlled study of fluvoxamine in the treatment of panic disorder. Neuropsychopharmacology 10(3 Suppl.): P58-P63.
87. Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH, Lydiard B, McElroy S, Zajecka J, Chapman D, Clary C, Harrison W. 2000. Multicentre double-blind comparison of sertraline and desipramine for concurrent obsessive compulsive and depressive disorders. Arch Gen Psychiatry 57: 76-82.
88. Holland RL, Fawcett J, Hoehn-Daric R, Munjack DJ, Roy-Byrne PP. 1994. Long-term treatment of panic disorder with fluvoxamine in outpatients who had complete double-blind studies. Neuropsychopharmacology 10(Suppl.): 102.
89. Insel T, Mueller E, Alterman I, Linnoila M, Murphy DL. 1985. OCD and serotonin: is there a connection? Biol Psychiatry 20: 1174-1188.
90. Invernizzi R, Belli S, Samanin R. 1992. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 584: 322-324.
91. Jacobsen FM. 1991. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 52: 217-220.
92. Jacobsen FM. 1995. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 56: 423-429.
93. Jenck F, Moreau JL, Berendsen HH, Boes M, Broekkamp CL, Martin JR, Wichmann J, Van Delft M. 1988. Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol 8: 161-168.
94. Jenck F, Martin JR, Moreau JL. 1999. The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats. J Psychopharmacol 13: 166-170.
95. Jenike MA, Baer L. 1988. An open trial of buspirone in obsessive-compulsive disorder. Am J Psychiatry 145: 1285-1286.
96. Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, Summergrad P, Seymour R, Ricciardi J. 1990a. A controlled trial of fluvoxamine in OCD: implications for a serotonergic theory. Am J Psychiatry 147: 1209-1215.
97. Jenike MA, Baer L, Greist JH. 1990b. Clomipramine versus fluoxetine in OCD: a retrospective comparison of side effects and efficacy. J Clin Psychopharmacol 10: 122-124.
98. Jenike MA, Baer L, Buttolph L. 1991. Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. J Clin Psychiatry 52: 13-14.
99. Jenkins SW, Robinson DS, Fabre Jr LF, Andary JJ, Messina ME, Reich LA. 1990. Gepirone in the treatment of major depression. J Clin Psychopharmacol 10(Suppl.): 77S-85S.
100. Joffe RT, Schuller DR. 1993. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 54: 269-271.
101. Judge R, Steiner M. 1996. The long-term efficacy and safety of paroxetine in panic disorder. Presented at the 28th CINP Congress, Melbourne, 1996.
102. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. 1995. Sertraline for social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 152: 1368-1371.
103. Keller MB, Gelenberg AJ, Hirschfeld RM, Rush AJ, Thase ME, Kocsis JH, Markowitz JC, Fawcett JA, Koran LM, Klein DN, Russell JM, Kornstein SG, McCullough JP, Davis SM, Harrison WM. 1998a. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 59: 598-607.
104. Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran L, Schatzberg A, Russell J, Hirschfeld R, Klein D, McCullough JP, Fawcett JA, Kornstein S, LaVange L, Harrison W. 1998b. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled study. JAMA 280: 1665-1672.
105. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Highes M, Eshleman S. Wittchen HU, Kendler KS. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51: 8-19.
106. Kiev A, Feiger A. 1997. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 58: 146-152.
107. Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J. 1997. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 96: 343-346.
108. Koran LM, Mueller K, Maloney A. 1996. Will pindolol augment the response to a serotonin reuptake inhibitor in obsessive-compulsive disorder? [Letter]. J Clin Psychopharmacol 16: 253-254.
109. Kronig MH, Apter J, Bystritsky A, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenberg R, Robinson D, Roy-Byrne P, Phillips K, Du Pont IJ. 1999. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 19: 172-176.
110. Laakmann G, Schule C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S. 1998. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology Berl 136: 357-366.
111. Lapierre YD. 1991. Controlling acute episodes of depression. Int Clin Psychopharmacol 6(Suppl.): 23-35.
112. Lecrubier Y, Bakkler A, Dunbar G, Judge R, the Collaborative Paroxetine Panic Study Investigators. 1997a. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 95: 145-152.
113. Lecrubier Y, Judge R, the Collaborative Paroxetine Panic Study Investigators. 1997b. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand 95: 153-160.
114. Lepola U, Koponen H, Leinonen E. 1994. Citalopram in the treatment of social phobia: a report of three cases. Pharmacopsychiatry 27: 186-188.
115. Londborg PD, Wolkow R, Smith WT, Du Boff E, England D, Ferguson J, Rosenthal M, Weise C. 1998. Sertraline in the treatment of panic disorder: a multi-site, double-blind, placebo-controlled, fixed dose investigation. Br J Psychiatry 173: 54-60.
116. Mancini C, van Ameringen MV. 1996. Paroxetine in social phobia. J Clin Psychiatry 57: 519-522.
117. Marcoli M, Maura G, Tortarolo M, Raiteri M. 1998. N-methyl-D-aspartate/nitric oxide/cyclic GMP pathway in rat cerebellum. J Pharmacol Exp Ther 285: 983-986.
118. Marcus RN, Mendels J. 1996. Nefazodone in the treatment of severe, melancholic, and recurrent depression. J Clin Psychiatry 57(Suppl. 2): 19-23.
119. Marek GJ, McDougle CJ, Price LH, Seiden LS. 1992. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology 109: 2-11.
120. Martins EA, Pigott TA, Bernstein SE, Doyle BB, Sunderland B, Smolka VM, Dubbert B. 1994. Sertraline in the treatment of patients with social phobia. Anxiety 1: 291-297.
121. Mendlewicz J. 1992. Efficacy of fluvoxamine in severe depression. Drugs 43(Suppl. 2): 32-37.
122. Michelson D, Lydiard RB, Pollack MH, Tamura R, Hoog SL, Tepner R, Demitrack MA, Tollefson G, The Fluoxetine Panic Disorder Study Group. 1998. Outcome assessment of clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry 155: 1570-1577.
123. Montgomery SA, Dunbar G. 1993. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 8: 189-195.
124. Montgomery SA, Kasper S. 1995. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol 9(Suppl. 4): 33-40.
125. Montgomery SA, Rasmussen JG, Tanghoj P. 1993. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 8: 181-188.
126. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D. 1994. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9: 47-53.
127. Mundo E, Bianchi L, Bellodi L. 1997. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. J Clin Psychopharmacol 17: 267-271.
128. Munjack DJ, Flowers C, Eagan TV. 1994. Setraline in social phobia. Anxiety 1: 196-198.
129. Murphy DL, Pigott TA. 1990. A comparative examination of a role for serotonin in obsessive-compulsive disorder, panic disorder, and anxiety. J Clin Psychiatry 51(Suppl.): 53-58.
130. Nappi G, Sandrini G, Granell F, Ruiz L, Cerutti G, Facchinetti F, Blandini F, Manzoni GC. 1990. A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline. Headache 30: 439-444.
131. Nutt DJ. 1998. Antidepressants in panic disorder: clinical and preclinical mechanisms. J Clin Psychiatry 59(Suppl. 8): 24-29.
132. Nutt DJ, Cowen PJ. 1987. Diazepam alters brain 5-HT function in man: implications for the acute and chronic effects of benzodiazepines. Psychol Med 17: 601-607.
133. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM. 1995. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 167: 374-379.
134. Olajide D, Lader M. 1987. A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states. J Clin Psychopharmacol 7: 148-152.
135. Pande AC, Sayler ME. 1993. Severity of depression and response to fluoxetine. Int Clin Psychopharmacol 8: 243-245.
136. Pato MT, Pigott TA, Hill JL, Grover GN, Bernstein S, Murphy DL. 1991. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 148: 127-129.
137. Patris M, Bouchard JM, Bougerol T, Charbonnier JF, Chevalier JF, Clerc G, Cyran C, Van Ameringen P, Lemming O, Hopfner Petersen HE. 1996. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 11: 129-136.
138. Patten SB. 1992. The comparative efficacy of trazodone and imipramine in the treatment of depression. CMAJ 146: 1177-1182.
139. Pecknold JC, Matas M, Howarth BG, Ross C, Swinson R, Vezeau C, Ungar W. 1989. Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry 34: 766-771.
140. Pecknold JC, Luthe L, Scott-Fleury MH, Jenkins S. 1993. Gepirone and the treatment of panic disorder: an open study. J Clin Psychopharmacol 13: 145-149.
141. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F. 1999. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch Gen Psychiatry 56: 375-379.
142. Pigott TA, L'Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL. 1992. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12: 156-162.
143. Pohl RB, Wolkow RM, Clary CM. 1998. Sertraline in the treatment of panic disorder: a double-blind multicenter study. Am J Psychiatry 155: 1189-1195.
144. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R. 1998. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 55: 1010-1016.
145. Rapaport M, Coccaro E, Sheline Y, Perse T, Holland P, Fabre L, Bradford D. 1996. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 16: 373-378.
146. Rasmussen S, Eisen J, Pato M. 1993. Current issues in the pharmacologic management of OCD. J Clin Psychiatry 54: 4-9.
147. Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran LM, Liebowitz M, Lydiard RB, McElroy S, Mendels J, O'Connor K. 1997. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 12: 309-316.
148. Rasmussen S, Goodman W, Greist J, Jenike M, Kozak M. Fluvoxamine in the treatment of OCD: a multicenter double-blind, placebo-controlled study in outpatients. Am J Psychiatry (in press).
149. Rausch JL, Ruegg R, Moeller FG. 1990. Gepirone as a 5-HT1A agonist in the treatment of major depression. Psychopharmacol Bull 26: 169-171.
150. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. 1996. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 32: 167-173.
151. Rickels K, Amsterdam JD, Clary C, Puzzuoli G, Schweizer E. 1991. Buspirone in major depression: a controlled study. J Clin Psychiatry 52: 34-38.
152. Rickels K, Schweizer E, Clary C, Fox I, Weise C. 1994. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 164: 802-805.
153. Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C. 1997. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol 17: 272-277.
154. Ringold AL. 1994. Paroxetine efficacy in social phobia. J Clin Psychiatry 55: 363-364.
155. Robert P, Montgomery SA. 1995. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 10(Suppl. 1): 29-35.
156. Robinson DS, Alms DR, Shotriya RC, Messina M, Wickramaratne P. 1989. Sertotonergic anxiolytics and treatment of depression. Psychopathology 22(Suppl. 1): 27-36.
157. Robinson DS, Rickels K, Feighner J, Fabre Jr LF, Gammans RE, Shrotriya RC, Alms DR, Andary JL, Messina ME. 1990. Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 10(Suppl. 3): 67S-76S.
158. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. 1997. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 95: 444-450.
159. Rosenberg C, Damsbo N. Fuglum E, Jacobsen LV. 1994. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int Clin Psychopharmacol 9(Suppl. 1): 41-48.
160. Rush AJ, Koran LM, Keller MB, Markowitz JC, Harrison WM, Miceli RJ, Fawcett JA, Gelenberg AJ, Hirschfeld RM, Klein DN, Kocsis JH, McCullough JP, Schatzberg AF, Thase ME. 1998. The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry 59: 589-597.
161. Saxena S, Wang D, Bystritsky A, Baxter Jr LR. 1996. Risperidone augmentation of SSRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 57: 303-306.
162. Schneier FR, Garfinkel R, Kennedy B, Campeas R, Fallon B, Marshall R, O'Donnell L, Hogan T, Liebowitz MR. 1996. Ondansetron in the treatment of panic disorder. Anxiety 2: 199-202.
163. Schweizer EE, Amsterdam J, Rickels K, Kaplan M, Droba M. 1986. Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull 22: 183-185.
164. Sheehan DV, Raj AB, Sheehan KH, Soto S. 1990. Is buspirone effective for panic disorder? J Clin Psychopharmacol 10: 3-11.
165. Sheehan DV, Raj BA, Trehan RR, Knapp EL. 1993. Serotonin in panic disorder and social phobia. Int Clin Psychopharmacol 8(Suppl. 2): 63-77.
166. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, Mason J. 1993. Selective serotonin reuptake inhibitors: meta analysis of efficacy and acceptability. Br Med J 306: 683-687.
167. Sramek JJ, Fresquet A, Amrio-Landais G, Hourani J, Jhee SS, Martinez L, Jensen CM, Bolles K, Carrington AT, Cutler NR. 1996. Establishing the maximum tolerated dose of lesopitron in patients with generalized anxiety disorder: a bridging study. J Clin Psychopharmacol 16: 454-458.
168. Steffens DC, Krishnan KR, Helms MJ. 1997. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 6: 10-18.
169. Stein MB, Chartier MJ, Hazen AL, Kroft CD, Chale RA, Cote D, Walker JR. 1996. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 16: 218-222.
170. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. 1998. Paroxetine treatment of generalised social phobia (social anxiety disorder): a randomised controlled trial. JAMA 280: 708-713.
171. Stein MB, Fyer AJ. Davidson JR. Pollack MH, Wiita B. 1999. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156: 767-760.
172. Steiner M. 1995. Long-term treatment and prevention of relapse in OCD with paroxetine. Presented at the Annual Meeting of the American Psychiatric Association, Miami, 1995.
173. Sternbach H. 1990. Fluoxetine treatment of social phobia [Letter]. J Clin Psychopharmacol 10: 230-231.
174. Tancer ME. Uhde TW. 1997. Role of serotonin drugs in the treatment of social phobia. J Clin Psychiatry 58(Suppl. 5): 50-54.
175. Thase ME. 1999. Antidepressant treatment of the depressed patients with insomnia. J Clin Psychiatry 60(Suppl. 17): 28-31.
176. Tignol J. 1993. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 13(Suppl. 2): 18-22.
177. Tignol J, Stoker MJ, Dunbar GC. 1992. Paroxetine in the treatment of melancholia and severe depression. Int Clin Psychopharmacol 7: 91-94.
178. Tollefson GD, Birkett M, Koran L, Genduso L. 1994b. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry 55(Suppl.): 69-76.
179. Tollefson GD, Rampey Jr AH, Potvin JH, Jenike MA, Rush AJ, Kominguez RA, Koran LM, Shear MK, Goodman W, Genduso LA. 1994a. A multicenter investigation of fixed-dose fluoxetine in the treatment of OCD. Arch Gen Psychiatry 51: 559-567.
180. van Ameringen M, Mancini C, Streiner DL. 1993. Fluoxetine efficacy in social phobia. J Clin Psychiatry 54: 27-32.
181. van Ameringen M, Mancini C, Streiner D. 1994. Sertraline in social phobia. J Affect Disord 31: 141-145.
182. van Ameringen M, Mancini C, Wilson C. 1996. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 39: 115-121.
183. van Vliet IM, den Boer JA, Westenberg HGM. 1994. Psychopharmacological treatment of social phobia; a double-blind, placebo-controlled study with fluvoxamine. Psychopharmacology (Berl) 115: 128-134.
184. van Vliet IM, Westenberg HGM, den Boer JA. 1996. Effects of the 5-HT1A receptor agonist flexinoxan in panic disorder. Psychopharmacology 127: 174-180.
185. van Vliet IM, den Boer JA, Westenberg HGM, Pian KL. 1997. Clinical effects of buspirone in social phobia: a double-blind, placebo-controlled study. J Clin Psychiatry 58: 164-168.
186. van Vliet IM, Westenberg HGM, den Boer JA. 1999. Pindolol does not augment the panicolytic effects of fluvoxamine in panic disorder patients. Biol Psychiatry (submitted).
187. Wade AG, Lepola U, Koponene HJ, Pedersen V, Pedersen T. 1997. The effect of citalopram in panic disorder. Br J Psychiatry 170: 549-553.
188. Wheadon DE, Bushnell WD, Steiner M. 1993. A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive compulsive disorder. Presented at the 32nd Annual Meeting of the American College of Neuropsychopharmacology, 1993.
189. Wilcox CS, Ferguson JM, Dale JL, Heiser JF. 1996. A double-blind trial of low-and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 32: 335-342.
190. Wise CD, Berger BD, Stein L. 1972. Benzodiazapines: anxiety-reducing activity by reduction of serotonin turnover in the brain. Science 177: 180-183.
191. Yamadera H, Suzuki H, Nakamura S, Endo S. 1999. Effects of trazodone on polysomnography, blood concentration and core body temperature in healthy volunteers. Psychiatry Clin Neurosci 53: 189-191.
192. Zohar J, Insel T. 1987. OCD: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 22: 667-687.
193. Zohar J, Judge R. 1996. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 169: 468-474.